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The average cost per prescription was R634.76 for donepezil, and R551.35 for 
memantine. Only 5.27% of patients were prescribed more than one active ingredient 
for Alzheimer’s disease during the year (mostly donepezil or galantamine, together 
with memantine). Average Prescribed Daily Doses (PDDs) of all active ingredients 
were generally lower than their respective Deﬁned Daily Doses (DDDs). The average 
PDD for donepezil was 7.45 mg (DDD  7.5 mg), galantamine 13.56 mg (DDD  
16 mg), for memantine was 17.46 mg (DDD  20 mg) and for rivastigmine was 
6.89 mg (DDD  9 mg). CONCLUSIONS: The results were similar to those of previ-
ous South African studies. Treatment outcomes could not be measured and it is recom-
mended that qualitative studies be undertaken to determine the cost-effectiveness of 
the different treatment options according to family members and caretakers.
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OBJECTIVES: Prescribing an initial optimum therapeutic dose while avoiding dose-
related side effects is important in the treatment of major depressive disorder (MDD). 
Many factors may inﬂuence a physician’s decision on an antidepressant choice and 
starting dose. The purpose of the present study was to identify the pretreatment predic-
tors of initial high-dose prescription of duloxetine in patients with MDD in real world 
clinical settings. METHODS: A total of 10,128 patients with MDD who were selected 
from a large commercially administrative claims database and were initiated on 
duloxetine between July 1, 2005 and June 30, 2006 were included in the analysis. 
Patients had no prescriptions of duloxetine in the 6 months prior to duloxetine treat-
ment. For patients who had continuous enrollment for 12 months prior to duloxetine 
treatment, the associations between demographic characteristics and pre-initiation 
clinical variables in the prior 1 year and initial high-dose (60 mg/day) prescription 
compared with average dosage (60 mg/day) prescription were examined by logistic 
regression. RESULTS: Of the sample, 31.2% were initially prescribed duloxetine less 
than 60 mg/day; 62.1%, 60 mg/day; and 6.8%, 60 mg/day. Compared with average-
dose patients, high-dose patients had more comorbidities; used more benzodiazepine, 
anxiolytics, atypical antipsychotics, lithium, psychostimulants, and anticonvulsants; 
and used more medical care services with higher pharmacy and medical costs in the 
prior 1 year. After adjustment for health plan type and geographic region of residence, 
the following factors were independently associated with initial high-dose prescription: 
prior use of psychostimulants (OR  1.45), no prior use of selective serotonin reuptake 
inhibitors (OR  1.28), physician specialty (psychiatrist vs. non-psychiatrist, OR  
1.43), and high medical cost in the prior 1 year (OR  2.12). CONCLUSIONS: 
 Multiple demographic and clinical characteristics and prior health care service utiliza-
tion are associated with initial high-dose duloxetine prescription. High-dose patients 
may represent a group of complex patients with high medical cost who need intensive 
medical intervention.
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OBJECTIVES: The appropriate and optimal health care resources of schizophrenic 
patients could beneﬁt from identifying predictive factors for hospitalization. The 
purpose of this study was to identify those factors of hospitalization for French 
schizophrenic patients out of a 2 years prospective cohort of 288 patients. METHODS: 
This study collected clinical, patient reported outcomes, patient management, care 
giver involvement and resource utilizations data every six months. The patients who 
were at least once hospitalized during the study were compared to the patients who 
were not hospitalized during the study. Predictive factors of hospitalization were 
identiﬁed by using a Cox model with all appropriate variables. RESULTS: To be under 
antidepressant/depressed, to have negative attitude toward medicine and former hos-     
pitalizations appear to be good predictors of hospitalisation in French schizophrenic 
patients. While living alone and subjective side effect were associated to reduce the 
risk of hospitalisation. Depression is known to be associated to poor outcome however 
few comprehensive studies include depression as a confounding factor. Negative atti-
tude toward medicine as well as former hospitalisation are likely to be associated to 
increase the risk of hospitalisation. Unexpectedly perceived side effects and living alone        
were associated to reduce hospitalisation. The authors do not have clear explanation 
but hypothesis that would require to be tested in further studies. CONCLUSIONS: 
Unless appropriate confounding variables are included in resource utilization studies, 
results should considered with great caution.
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OBJECTIVES: to assess the prevalence, incidence and persistence of AntiDepressant         
(AD) drug therapy in an area of Campania, a region in the South of Italy, during the 
years 2005–2007. METHODS: we collected, from an administrative prescription      
database covering a population of 441,317 individuals, all prescriptions for ADs 
reimbursed in the years 2005–2007. We calculated the number of subjects receiving 
at least one ADs prescription, to estimate the annual prevalence and incidence of AD 
users. Among incidence users we evaluated the percentage of individuals remaining 
on therapy at 12 months following the ﬁrst observed AD prescription. The cumulative 
persistence of each medication was estimated using the Kaplan-Meier method. We      
identiﬁed users of different ADs types: tricyclic antidepressants (TCAs), selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibi-    
tors (SNRIs) and other antidepressants.   RESULTS: A progressive rise in prevalence     
rates was observed during the 3-years period. 1-year prevalence of AD use was 5.08 
per 100,000 inhabitants in the year 2007. Prevalence was higher for females (2005: 
5.67; 2006: 6.15; 2007: 6.61) and increased during three years period with increasing 
age. Prevalence of SSRI usage markedly increased from 3.45 in 2005 to 4.04 in 2007. 
A 1-year incidence of AD treatment was 2.79 per 100,000 person-year in 2006. SSRIs 
accounted for almost two-thirds of total new treatments with ADs. The analysis of 
therapy persistence revealed that the 80% of AD users discontinued medication within 
60 days; there are no difference among different drug classes. CONCLUSIONS: The 
results of the study indicated an increasing prevalence of AD medication usage during 
the 2005–2007 years. This increase appears to be mostly related to SSRI, in particular 
those recently marketed. The non-persistence is very frequent in AD users, only rarely 
the duration of treatment was consistent with recommendations for depression 
therapy.
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As a ﬁrst step to model schizophrenia, we are proposing a research project aimed at 
better understanding the factors associated with speciﬁc disease states associated 
with schizophrenia. OBJECTIVES: To evaluate the factors associated with the risk of 
being in a speciﬁc disease state of schizophrenia. METHODS: The model was based 
on data from RAMQ and Med-Echo databases. A total of 12,754 newly diagnosed 
patients with schizophrenia patients were identiﬁed. Six discrete disease states were 
deﬁned within the model (ﬁrst episode—FE, low dependency state—LDS, high depen-
dency state—HDS, Stable, Well and Death) and patients’ movements between these 
disease states enabled 17 risks to be identiﬁed. To evaluate factors associated to the 
risk of being in each disease state, we constructed ﬁve risk functions based on Cox 
proportional hazard analysis for competing risks. The risk factors included in the 
models were age, gender, social assistance status, severity of schizophrenia, depression, 
anxiolytic drugs use and other mental disorders. RESULTS: After the FE of schizo-
phrenia, 69.8% of patients transitioned to LDS, 11.2% to HDS, 1% to the death 
state and 18% into the Well state. Being male (HR: 0.93, 95% CI: 0.89–0.97) or 
older (HR: 0.94, 95% CI: 0.91–0.96) was associated with a decreasing risk of moving 
to LDS after being FE. In contrast, being on social assistance, depressed, using anxio-
lytic drugs or being diagnosed with other mental disorders were associated with 
an increased risk of being in a LDS after a FE, ranging from 1.11 to 1.55 folds. 
CONCLUSIONS: Some of our results are consistent with those obtained from the 
published literature. Based on these risk functions we estimate individual transition 
probabilities that will be used in the ﬁrst Canadian model of schizophrenia incorporat-
ing transition probabilities adjusted for individual risk factors proﬁles using Canadian 
data.
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OBJECTIVES: In Western Hungary the number of women with hypertension increased 
with 21%, the number of patients with ischemic heart problems increased with 46% 
between 2005 and 2007. The most probable reason of this sudden increase among 
the life quality factors is the increasing of chronic stress. The rate of chronic stress 
and the effectiveness of coping were measured between workers from a regional mul-
tinational ﬁrm with a cross sectional examination in 2008. METHODS: Sampling is 
representative regarding to the Western Hungarian population, 900 workers were 
examined with unknown presumption. Data collection was made with Richard Rahe 
Short Questionnaire about Stress and Coping standard measurement device. The 
analysis of the data was done with SPSS 17.0 and Epi Info 3.5.1 programs, two sample 
t-test and logistic regression calculation was made. RESULTS: From the ﬁve scales 
measuring stress women showed alarming signs on three scales (sanitary problems, 
psychological symptoms and the A- and C-type personal characteristic scales), and 
men on one scale (the A- and C-type personal characteristic). The difference is signiﬁ-
cant (p  0.000). From the ﬁve scales measuring coping men and women equally 
showed alarming signs on the social support scale as a deﬁcit. Women ﬁght against 
stress with less efﬁciency on the scale of habits related to health (p  0.001). The most 
deﬁning stress indicating factor in case of man is sanitary problems (OR  2.27, p  
0.02), and personal characteristics in case of woman (OR  3.34, p  0.002). The 
most important inﬂuencing factor in case of coping is the sense of coherence (at women 
OR  7.9, p  0.000, at men OR  4.5, p  0.000). CONCLUSIONS: This survey 
shows that chronic stress is complex, but it can be examined individually and in teams 
with proper methods. This topic is current in relation to national health: chronic 
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stress is one of the most important psychological background factors of before time 
mortality in Hungary.
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OBJECTIVES: To determine the impact of disease severity on duration of hospitali-          
zation in patients with schizophrenia in presence of the confounding variables.
METHODS: A post-hoc analysis of data collected in the GEO study, a prospective,            
non-interventional study observing German patients (n  655) with schizophrenia 
(ICD-10, F20) for up to two years was undertaken. Patients provided informed 
consent and were documented in inpatient (psychiatric clinics) and outpatient (psy-
chiatric ofﬁces, hospital outpatient wards) settings. Disease severity was measured by 
the Clinical Global Impression scale (CGI), which consists of Severity of Illness, Global 
Improvement, and Efﬁcacy Index items. Structural equation modelling (SEM) was 
applied to evaluate the impact of disease severity on duration of hospitalization. 
Confounding variables (age at diagnosis, gender and treatment regimen) were tested 
in the models evaluating the inﬂuence of disease severity on duration of hospitaliza-
tion. The models were tested in an exploratory way using the Mplus Version 5.2. All 
indices (C2, P, C2/df, CFI, RMSEA, PCLOSE) suggested a good model ﬁt. RESULTS: 
Patients (52.7% males) were on average 41.7 years old, had a mean BMI of 26.4 kg/ 
m2, were statutorily insured (97.0%), predominantly single (60.8%) and not employed 
(71.2%) at enrolment. Age at diagnosis, antipsychotic treatment regimen and disease 
severity were independently associated with duration of hospitalization (B  0.127, 
0.270 and 0.174, respectively), indicating that younger age at diagnosis of schizophre-
nia, treatment with olanzapine and less severe disease condition are associated with 
shorter duration of hospitalization. Gender had no effect on duration of hospitaliza-
tion (B  0.027). CONCLUSIONS: Treatment regimen and age at diagnosis play an        
important role in the associations between disease severity and duration of hospitaliza-
tion. Advanced techniques such as SEM are important tools for analyzing data in that 
they are able to detect associations, which univariate tests may fail to identify. Further 
research is needed to conﬁrm our ﬁndings.
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OBJECTIVES: To estimate the impact of duloxetine reimbursement in major depres-
sive disorder (MDD) treatment on public payer’s budget in Poland. METHODS: The 
analysis was performed in 5-year time horizon from the public payer (National Health 
Fund, NFZ) perspective . Only costs of medicines were included. On the base of sales 
data for years 2004–2008 linear regression was conducted to predict consumption of 
antidepressants in Poland. Cost data of medicines were obtained from Ministry of 
Health and other sources in case of lack of reimbursement. Duloxetine market share 
and alternative medicines replacement was estimated on the base of antidepressants 
sale data from European countries. One-way sensitivity analysis were performed for 
the key input parameters. RESULTS: Assuming that duloxetine is not reimbursed the 
expenditure on all antidepressants from NHF perspective will be 138.83 milion PLN 
(mPLN) in year 2010 and 171.37 mPLN in year 2014. In case of reimbursement of 
duloxetine the expenditures will increase by 0.07 mPLN in year 2010 and by 8.82 
mPLN in year 2014. CONCLUSIONS: Our ﬁndings suggest that decision concerning 
reimbursement of duloxetine should not lead to important increase of total expendi-
tures on the MDD treatment from on public payer’s perspective.
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INJECTABLE IN THE GERMAN HEALTH CARE SYSTEM
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OBJECTIVES: Social health insurance cost of care for patients with schizophrenia 
(ICD-10: F20-F25) are mainly inﬂuenced by hospitalization and use of antipsychotic 
medication. We determined the budget impact of long acting injectable risperidone 
(RLAI) for the German health care system in comparison to other antipsychotics 
(N05A, N05A1, Quetiapine). METHODS: The perspective of the social health insur-
ance (GKV) was adopted (one year time horizon). An Excel(R) based hypothetical 
budget impact model calculating cost consequences of using antipsychotic medication 
was developed accounting for hospital and medication cost only. Patient numbers and 
prescription shares were calculated using IMS-Health Disease Analyzer data. Medica-
tion costs are GKV net costs calculated by using recent list prices (06/09) and GKV 
utilization data. Parameters on hospitalization and relapse were derived from pub-
lished literature, Federal Ofﬁce of statistics and clinical trial data. Starting from status 
quo we speciﬁcally looked at new patients to be treated with antipsychotics. In a base 
case we assumed that new patients were distributed to the existing treatment options 
according to current patient share. Starting from this we hypothetically increased the 
patient share of RLAI by lowering the share of other antipsychotic treatments. 
RESULTS: We included 192,732 patients. 8000 new patients were added, 304 of 
which were treated with RLAI, 673 with Quetiapine. Costs for new patients would 
be a48,641,318. Increasing the treatment share of RLAI to 5% by shifting patients 
from Quetiapine to RLAI would decrease costs to a48,543,486 with increased medica-
tion cost being more than offset by decreased hospitalization costs. Switching new 
patients from all N05A1 treatments would decrease costs to a48,625,655. Sensitivity 
analysis conﬁrmed the result that increasing treatment with RLAI would save costs. 
CONCLUSIONS: Our analysis suggests that extending the patient share of RLAI in 
new patients suffering from schizophrenia would decrease the overall cost spent on 
medication and hospitalization.
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OBJECTIVES: This study was intended to provide a detailed account of the labelled 
drug-related health expenditure of countries in Europe in 2005, and make a compre-
hensive assessment of the spending by considering the health spending to GDP ratio 
and the health spending per capita. METHODS: In 2007, the European Monitoring 
Centre for Drugs and Drug Addiction network of national focal points (NFPs) set up 
in the 27 EU Member States, Norway, and the candidate countries to the EU, identiﬁed 
labelled drug-related expenditure per country. The NFPs were asked to list any budg-
eted drug-related funds found after reviewing central, regional and local government 
ﬁnancial reports for the 2005 ﬁscal year. Labelled expenditure was classiﬁed by means 
of the International Classiﬁcation of the Functions of Government (COFOG). 
RESULTS: Health expenditure was reported by 10 countries. Total amount reported 
was a1.38 billion, the highest proportion being under outpatient (68%) and hospital 
services (16%), followed by medical products (7%) and public health services (7%). 
By country, labelled health expenditures ranged from a0.1 million (Slovakia) to a923.3 
million (UK), representing between 0.0003% and 0.051% of their GDP respectively. 
When plotted, the health expenditure per capita showed a positive association with 
the GDP per capita across countries (r  0.70). While there is an overall tendency for 
countries with higher GDP to spend a greater proportion of their GDP on drug-related 
health, there is a wide variation since GDP is not the sole factor inﬂuencing health 
expenditure amounts. CONCLUSIONS: Several countries have a considerable amount 
and quality of information on drug-related health public expenditure, facilitating 
public analysis and debate. These ﬁgures are ultimately intended to enhance policy-
makers’ decision-making on drug-related health policy. Public expenditure must even-
tually be complemented by undertaking economic evaluations where expenditure is 
considered in the perspective of the beneﬁts obtained by its allocation.
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OBJECTIVES: To compare costs of treating patients with major depressive disorder 
(MDD) with escitalopram versus duloxetine in Spain and to assess the 5-year budget-
ary impact (BI) of different scenarios of escitalopram and duloxetine market share 
dynamics. METHODS: An evaluation of 6-month per patient costs associated with 
escitalopram versus duloxetine treatment was conducted alongside a 24-week double-
blind randomized multinational study in adult outpatients with MDD. Health care 
resource use and sick leave were evaluated using a Health Economic Assessment 
questionnaire. Unit costs of health care services were obtained from standard Spanish 
sources. For the 5-year BI analyses, scenario 1 based the growth of escitalopram and 
duloxetine market shares on conservative Spanish forecasts; scenario 2 assumed a 
higher growth of escitalopram share in MDD due to its superior clinical proﬁle, with 
a conservative 1% annual intake from duloxetine market share growth rate. Popula-
tion and MDD prevalence data were obtained from standard Spanish sources. 
RESULTS: For the total 24-week study period, per patient costs were a986 for esci-
talopram and a1,593 for duloxetine – a savings of a608 in favor of escitalopram. Sick 
leave was the major driver of overall cost in both treatment groups (60–70%). Given 
a Spanish population of 45.2 million and 4% prevalence of MDD, the BI analysis 
revealed treatment with escitalopram yielded savings amounting to a174 million over 
5 years for the total patient cohort. CONCLUSIONS: Escitalopram is associated 
with signiﬁcant cost savings compared with duloxetine. Indirect costs of sick leave 
accounted for the greatest portion of total costs. Reduced health care use and sick 
leave costs suggest that escitalopram could be a preferred therapeutic alternative to 
duloxetine in treating MDD, thereby bringing substantial overall cost savings over 5 
years and providing additional evidence that escitalopram is an attractive option for 
ﬁrst-line treatment of MDD in Spain.
